Frost & Sullivan: Diagnostic and Therapeutic Potential of microRNAs Stimulate Need for More Research Tools
-- Product innovation and the development of high-qualitative assays are the need of the hour
LONDON, Sept. 4, 2013 /PRNewswire/ -- Rapid growth in microRNA (miRNA) research over the past two years, owing to its diagnostic and therapeutic potential, has fuelled development in the global miRNA tools and services market. Of the various miRNA technologies, which include quantitative real-time polymerase chain reaction (qRT PCR), microarrays and functional tools, qRT PCR remains the fastest-growing, while microarray is gradually being replaced by next-generation sequencing platforms.
New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), Global Analysis of MicroRNA Tools and Services Market, finds that the tools side of the market earned revenues of $110.0 million in 2012 and estimates this to more than double to reach $247.7 million in 2017. The US contributed to about 47% of the revenue followed by 36.7% from Europe, while leaving the rest to APAC and ROW. The miRNA services market earned revenues of $35.1 million in 2012 and this is expected to grow to $63.3 million in 2017. The end users covered are academic and research institutes, core facilities, and pharmaceutical and biotech companies.
The growth of therapeutic and diagnostic enterprises, higher research funding and increased outsourcing to contract research organisations in the US will present immense opportunities for the miRNA tools and services market. At the same time, sequestration measures in the country will slow down market expansion. In Asia-Pacific, increased investments by foreign companies in emerging nations such as Japan, China and India will encourage local mergers and acquisitions and propel the market forward.
"As miRNA research evolves globally and more efficient products are required, the space is burgeoning with technology innovations," said Frost & Sullivan Healthcare Senior Research Analyst Divyaa Ravishankar. "Strategic alliances for product development are taking place, resulting in novel kits for qPCR and new mimics and inhibitors that help researchers shorten their project timeline and get more funding."
With more research laboratories entering the market and demand for commercial assays growing, researchers often look to obtain miRNA tools through routes other than commercial miRNA microarray vendors. For instance, researchers can produce in-house miRNA microarrays or their own miRNA knockdown and up-regulation tools. This is a major underlying limitation to the market, which is also challenged by potential pricing pressures.
Nevertheless, the impact of these restraints will decline as miRNA functional analysis matures and vendors enhance tools. Eventually, commoditisation will lead to a drop in costs and nullify any cost and quality benefits of in-house production.
"To sustain product value until then, market participants must continue to offer technology improvements and differentiated features, and strategically compete without making deep pricing cuts that may irreversibly damage market potential," suggested Ravishankar. "Providing complete workflow solutions and discounts when a customer purchases products along with several different portfolios will simplify purchasing and attract new customers."
If you are interested in more information on this research, please send an email to Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com
Global Analysis of MicroRNA Tools and Services Market is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan's related research services include: Strategic Analysis of the U.S. Next-Generation Sequencing Services Market, European PCR Reagent Market for Research Applications and Clinical Diagnostic, U.S. qPCR Reagents Market, European Next-Generation Sequencing Markets, and Analysis of MicroRNA Tools and Services Market in Europe. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com
Share this article